Cato Mørk

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis Associations

H Zachariae, Robert Zachariae, K Blomqvist et al. · Acta Dermato Venereologica · 2002 · 219 citations · Full text

A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp

Stine Regin Wiegell, Susanne Fabricius, Ida‐Marie Stender et al. · British Journal of Dermatology · 2011 · 171 citations

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll et al. · JAMA · 2021 · 147 citations · Full text

Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study

Stine Regin Wiegell, Susanne Fabricius, Monika Gniadecka et al. · British Journal of Dermatology · 2012 · 146 citations